Canada markets closed

AxoGen, Inc. (AXGN)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
6.56+0.15 (+2.34%)
At close: 04:00PM EDT
6.56 0.00 (0.00%)
After hours: 04:30PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close6.41
Open6.40
Bid6.52 x 100
Ask6.58 x 100
Day's Range6.40 - 6.77
52 Week Range3.45 - 10.83
Volume213,331
Avg. Volume375,229
Market Cap286.702M
Beta (5Y Monthly)1.02
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateJan 27, 2010
1y Target EstN/A
  • GlobeNewswire

    Axogen Announces First Surgical Implants of Avive+ Soft Tissue Matrix™

    ALACHUA, Fla. and TAMPA, Fla., April 29, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, announces the first surgical implantations of its newest product, Avive+ Soft Tissue Matrix™. “We are excited to expand our offering in nerve protection with the introduction of this resorbable barrier to support the critical phases of healing for nerve injuries,” said Karen Zaderej, chairman, CEO,

  • GlobeNewswire

    Axogen, Inc. to Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024

    ALACHUA, Fla. and TAMPA, Fla., April 16, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report first quarter 2024 financial results on Thursday, May 2, 2024, before the market opens. Axogen management will host an investment-community conference call and webcast at 8 a.m. ET following the release. Investors interested in participating in the conference call

  • GlobeNewswire

    Axogen, Inc Reports 2023 Fourth Quarter and Full-Year Financial Results

    ALACHUA, Fla. and TAMPA, Fla., March 05, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the fourth quarter and full-year ended December 31, 2023. Fourth Quarter 2023 Financial Results and Business Highlights Fourth quarter revenue was $42.9 million, an 18.7% increase compared to the fourth quarter of 2022.The Company estimate